Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRTH-101 |
Synonyms | |
Therapy Description |
PRTH-101 is a humanized monoclonal antibody targeting DDR1, which potentially prevents immune exclusion in the tumor microenvironment and enhances antitumor response (PMID: 37328286). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRTH-101 | PRTH101|PRTH 101 | DDR1 Inhibitor 10 | PRTH-101 is a humanized monoclonal antibody targeting DDR1, which potentially prevents immune exclusion in the tumor microenvironment and enhances antitumor response (PMID: 37328286). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05753722 | Phase I | Pembrolizumab + PRTH-101 PRTH-101 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Recruiting | USA | 0 |